Posted by Michael Wonder on 16 Feb 2023
NICE says evidence that COVID-19 treatment Evusheld is effective in protecting vulnerable adults against current variants is lacking as it announces new rapid update process for COVID-19 medicines
16 February 2023 - NICE has today issued draft guidance for public consultation which does not recommend Evusheld for preventing COVID-19 in adults who are unlikely to have an adequate immune response to COVID-19 vaccination, or who can’t be vaccinated.
NICE has also announced that it is developing a new review process to update recommendations on the cost effectiveness of COVID-19 treatments so they can be made available more quickly to patients if they show promise against new variants and are found to be cost effective.
